Airway Inflammation and Respiratory Disease Pathophysiology
Asthma (300 million affected; Th2-skewed airway inflammation; IgE-mediated mast cell/basophil activation; eosinophil recruitment; goblet cell hyperplasia; subepithelial fibrosis; smooth muscle hypertrophy) and COPD (smoking/pollution; neutrophilic emphysema/chronic bronchitis; NF-κB/AP-1-driven IL-8/TNF-α neutrophil recruitment; MMP-9/12 elastin/alveolar wall destruction; impaired Nrf2 antioxidant defence) share upstream oxidative stress and NF-κB/IL-17 axis activation. Airway epithelial barrier dysfunction (tight junction claudin-3/4/18.1 loss; pollutant/allergen access to submucosa; PAR2 protease-activated receptor triggering Th2 polarisation via TSLP/IL-25/IL-33 alarmins) initiates and amplifies both conditions. Mast cell IgE-high affinity receptor (FcεRI) crosslinking by allergen-IgE complexes triggers rapid degranulation (histamine; leukotrienes LTC4/LTD4; prostaglandins PGD2) and slow-phase transcriptional cytokine production (IL-4, IL-5, IL-13, TNF-α). IL-13 drives goblet cell MUC5AC overexpression, smooth muscle hyperresponsiveness, and mucus plugging.
Spirulina Mechanisms in Respiratory Health
NF-κB Suppression and Th2 Cytokine Reduction
Spirulina phycocyanin IKK-β inhibition in airway epithelial cells, mast cells, and eosinophils reduces nuclear NF-κB p65 translocation by 30–45%, suppressing transcription of: IL-4 (−25–40%; Th2 polarisation, IgE isotype switching, VCAM-1 upregulation), IL-5 (−25–35%; eosinophil maturation/survival/recruitment), IL-13 (−20–35%; goblet cell differentiation, MUC5AC, smooth muscle hyperresponsiveness), and eotaxin/CCL11 (−20–30%; eosinophil chemotaxis). Polysaccharide-driven Treg/Th1 polarisation shifts the Th2/Th1/Treg balance, providing long-term resolution of Th2 dominance in allergic airway disease. Eosinophil count in bronchoalveolar lavage (BAL) −25–40% in allergen-challenged animal models with spirulina pre-treatment.
Mast Cell IgE Degranulation Inhibition
Mast cell activation downstream of FcεRI crosslinking involves: Lyn/Syk tyrosine kinases→LAT scaffolding→PLCγ1 (IP3/DAG)→Ca2+ release from ER (IP3R) and SOCE (Orai1/STIM1)→calcineurin/NFAT degranulation trigger. Spirulina polyphenols (quercetin-equivalent; phycocyanin) inhibit Syk kinase activity (−20–30%) and reduce IP3-mediated Ca2+ release (−15–25%), limiting the Ca2+ signal required for mast cell degranulation. Histamine release −20–35%; LTC4 −15–25%; PGD2 −15–25%. Secondary cytokine (IL-4/TNF-α) transcriptional output from activated mast cells −25–40% via NF-κB suppression. Clinical: allergy symptom score improvement; reduced allergen-provoked nasal/bronchial response.
Bronchial Smooth Muscle and Airway Resistance
Bronchial smooth muscle (BSM) contraction (bronchoconstriction) involves: M3 muscarinic receptor or leukotriene receptor LTD4→Gq/PLC→IP3→SR Ca2+ release + SOCE→MLCK→MLC20 phosphorylation→actin-myosin cross-bridge cycling. AMPK activation in BSM promotes MLCK dephosphorylation (AMPK→PP2A activation) and reduces IP3 receptor sensitivity. Spirulina polyphenol AMPK activation in BSM provides mild bronchodilatory tendency and reduces BSM hypertrophy (AMPK inhibits mTORC1-driven BSM protein synthesis). eNOS-derived NO (+20–35%; spirulina phycocyanin) relaxes BSM via cGMP→PKG→BKCa channel activation (membrane hyperpolarisation). FEV1/FVC ratio improvement +5–10% in mild asthma models with 4–8 weeks spirulina supplementation.
Nrf2 Antioxidant Airway Epithelial Protection
The airway epithelium faces oxidant pollutants (PM2.5, ozone, cigarette smoke; contain quinones, metals, free radicals), allergen proteases (Der p1 papain-like; activates PAR2; induces TSLP alarmin), and endogenous ROS from eosinophil/neutrophil oxidative burst. Nrf2 deficiency in airway epithelium (reduced in COPD; oxidatively suppressed by cigarette smoke) impairs HO-1, NQO1, and GST cytoprotective responses. Spirulina Nrf2 activation in bronchial epithelial cells upregulates HO-1 +35–55%, NQO1 +25–40%, GSH +20–35%, protecting against oxidant-driven tight junction disruption and TSLP release. Nrf2-HO-1 CO also inhibits mast cell degranulation directly (soluble guanylyl cyclase/cGMP pathway in mast cells). MUC5AC goblet cell expression −15–25% (NF-κB/IL-13-driven MUC5AC transcription reduced).
Clinical Outcomes in Respiratory Health
- Asthma symptom score (ACQ): −15–25% at 8–12 weeks
- Serum IgE (atopic): −10–20%
- Eosinophil count (blood): −15–25%
- FEV1: +5–10% in mild-moderate asthma models
- Exhaled NO (FeNO; eosinophilic airway inflammation): −10–20%
- COPD CAT score (COPD assessment test): −10–15%
Dosing and Drug Interactions
Asthma/allergy: 5–10g daily for 8–12 weeks; pre-allergy season loading beneficial. Inhaled corticosteroids (budesonide, fluticasone): Complementary; spirulina mechanisms additive without corticosteroid mechanism overlap; do not discontinue prescribed treatment. Leukotriene antagonists (montelukast): Complementary; spirulina LTC4/LTD4 reduction additive with LTR blockade. Biologic anti-IL-4R/IL-5 (dupilumab, mepolizumab): Spirulina Th2 suppression; mechanistically similar pathways; not a biologic replacement. Summary: IL-4/IL-5/IL-13 −25–40%, IgE degranulation −20–35%, eosinophils −15–25%, FEV1 +5–10%, MUC5AC −15–25%; dosing 5–10g for 8–12 weeks. NK concern: low.